Results 71 to 80 of about 3,351 (178)
Hematological Oncology, Volume 44, Issue 1, January 2026.ABSTRACT The management of chronic lymphocytic leukemia (CLL) in older patients requires careful balancing of therapeutic efficacy with the risks of treatment intolerance. Frailty assessment is increasingly recognized as a critical determinant of clinical outcomes, but its specific role in guiding therapy with second‐generation Bruton tyrosine kinase ...
Ernesto Vigna +84 more
wiley +1 more source
Hyperviscosity Syndrome Induced Bilateral Visual and Auditory Impairment in Therapy Resistant Waldenström Macroglobulinemia with MYD88 and CXCR4 Mutations [PDF]
, 2023 Hyperviscosity syndrome (HVS) is an emergent complication of Waldenström macroglobulinemia (WM) characterized by visual, neurologic, and rarely auditory impairment. We report a 69-year-old female with MYD88 and CXCR4-mutant WM who developed HVS resulting
Agarwal, Amit K +7 more
core +1 more source
British Journal of Haematology, Volume 208, Issue 1, Page 149-158, January 2026.Summary A high unmet need for novel, safe and effective therapies exists among older patients with non‐Hodgkin lymphoma (NHL). We report safety and efficacy of mosunetuzumab in a subgroup analysis of a phase I/II study, which examined the prognostic impact of age in 218 patients with relapsed/refractory (R/R) B‐cell NHL (B‐NHL; ≥65 years, n = 102; <65 ...
Swetha Kambhampati Thiruvengadam +11 more
wiley +1 more source
Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
Therapeutic Advances in Hematology, 2021 The current therapeutic approach in Waldenström’s macroglobulinemia (WM) is being driven by insights in disease biology and genomic landscape. Bruton’s tyrosine kinase (BTK) plays a key role in signaling pathways for the survival of WM clone.
Ioannis Ntanasis-Stathopoulos +3 more
doaj +1 more source
Zanubrutinib in lymphoproliferative disorders: a comprehensive review
Therapeutic Advances in Hematology, 2022 The availability of Bruton tyrosine kinase (BTK) inhibitors has brought about a paradigm shift in the treatment of patients with B-cell lymphomas and chronic lymphocytic leukemia.
Javier Muñoz +3 more
doaj +1 more source
British Journal of Haematology, Volume 208, Issue 1, Page 58-66, January 2026.Summary Several tools have been developed to provide prognostic indicators that are more accurate than chronological age alone because choosing the best treatment for older lymphoma patients is challenging. For older patients with diffuse large B‐cell lymphoma (DLBCL), one of these prognostic indicators is patient fitness; its definition has been ...
Vittorio Ruggero Zilioli +5 more
wiley +1 more source
Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed [PDF]
As treatments with BTK inhibitors and BCL2 inhibitors have replaced the use of chemoimmunotherapy in CLL in both first-line and relapsed patients, it becomes critical to rationalize their use and exploit the full potential of each drug.
Alberto Fresa +8 more
core +2 more sources
Frontiers in ImmunologyBackgroundCytokine release triggered by a hyperactive immune response is thought to contribute to severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2)–related respiratory failure.
Steven P. Treon +35 more
doaj +1 more source
Clinician Perspective on Once-Daily Zanubrutinib Dosing for B-Cell Malignancies at a Single Center
Clinical Medicine Insights: OncologyZanubrutinib, a next-generation, irreversible, highly potent, and selective Bruton tyrosine kinase inhibitor, is approved by the U.S. Food and Drug Administration to treat patients with B-cell malignancies in 2 dose regimens: 160 mg twice daily (BID) and
Mohit Narang, Courtney Horn, Edward Lee
doaj +1 more source